Intravenous NAD+ or nicotinamide riboside: what immediate tolerability monitoring captures
This registered comparison names intravenous NAD+, intravenous nicotinamide riboside, oral nicotinamide riboside and placebo among its study interventions.

This registered comparison names intravenous NAD+, intravenous nicotinamide riboside, oral nicotinamide riboside and placebo among its study interventions. Blood pressure and heart rate around the procedure are among the primary assessments. A short-term observation of vital signs is a different question from whether a product improves energy over months.
Two differences can change the comparison
Comparing two intravenous arms can hold the delivery route broadly similar while changing the substance. Comparing oral with intravenous delivery changes the route as well. Results under one comparison cannot be silently assigned to another. It also matters when the vital signs were recorded relative to the infusion. A labelled retail amount in a pen does not identify any of those research arms. Long-term safety, symptom change and immediate vital signs each require appropriately collected data.
Work out what the comparison group contributes
During an infusion, an observation recorded as the infusion proceeds and another recorded after the line is removed have distinct timings. A claim about immediate tolerability should name the substance infused, the observation period and the comparison group. It tells a reader little about how someone will feel during an ordinary week after treatment.
A tolerability comparison can also include how the participant experienced the procedure and whether it was completed. Those details should be distinguished from a blood-pressure value measured by staff. Even if both appear in one paper, one is a reported or observed event and the other is a physiological measurement with a specific time and unit.
Participant and measurement details
- People in the record: 53 (actual enrollment). Eligible ages: 40 years and older.
- Clinical setting: Healthy Aging.
- Named study interventions: NAD+ (nicotinamide adenine dinucleotide) IV, Niagen® (nicotinamide riboside) IV, Niagen® (nicotinamide riboside) oral, Placebo.
- Study design: interventional, randomized, parallel. Masking: double.
- Measured here: Blood pressure and heart rate around the assigned study procedure.
- Research locations listed in the record include: Franklin, United States.
- Study calendar in the registration: start 2023-11-13; primary completion 2024-03-08.
- Primary record: Nutraceuticals Research Institute. ClinicalTrials.gov, NCT06382688.
The NAD+ presentation sold in Bali does not reproduce an infusion environment or continuous observation. If a comparison mentions both oral NR and intravenous NAD+, ask which two arms support the particular claim and whether the outcome was immediate tolerability or a later effect.
